0
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
First delivery to Swedish patients with medical cannabis oil
STENOCARE A/S ("STENOCARE") and Emerald Health Therapeutics Inc ("Emerald") hereby announces that the first shipment and delivery of medical cannabis oil has been completed on December 23, 2020 to Sweden.
STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. The Swedish and Canadian Health authorities has completed the required certificates and the first shipment of medical cannabis oil is now being delivered to the Swedish patients. In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor applied for a prescription for treatment with medical cannabis oil.
STENOCARE is a leading supplier of prescription-based medical cannabis products for patients' treatment to help them improve quality of life, and for Sweden their Canadian supplier of high-quality medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.
Niels V. Olsen, anesthesiologist, D.M.Sc., at "Smärt och Psykiatri Centrum Malmö" is commenting:
"We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis. We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries"
Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:
"With this first shipment of medical cannabis oil to Sweden we have achieved several important milestones. First, the product is the first ever full spectrum medical cannabis oil product to be prescribed for treatment of Swedish patients. We look forward to following the efficacy of this treatment. Secondly, for STENOCARE it is an important milestone in our strategy to enter new markets and sell premium products together with our partners"
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE's Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
First delivery to Swedish patients with medical cannabis oil
STENOCARE A/S ("STENOCARE") and Emerald Health Therapeutics Inc ("Emerald") hereby announces that the first shipment and delivery of medical cannabis oil has been completed on December 23, 2020 to Sweden.
STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. The Swedish and Canadian Health authorities has completed the required certificates and the first shipment of medical cannabis oil is now being delivered to the Swedish patients. In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor applied for a prescription for treatment with medical cannabis oil.
STENOCARE is a leading supplier of prescription-based medical cannabis products for patients' treatment to help them improve quality of life, and for Sweden their Canadian supplier of high-quality medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.
Niels V. Olsen, anesthesiologist, D.M.Sc., at "Smärt och Psykiatri Centrum Malmö" is commenting:
"We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis. We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries"
Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:
"With this first shipment of medical cannabis oil to Sweden we have achieved several important milestones. First, the product is the first ever full spectrum medical cannabis oil product to be prescribed for treatment of Swedish patients. We look forward to following the efficacy of this treatment. Secondly, for STENOCARE it is an important milestone in our strategy to enter new markets and sell premium products together with our partners"
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE's Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
